Pharmaron Beijing Co., Ltd — Earnings Release 2019

Jan 21, 2020

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [117 x 33] intentionally omitted <==

Pharmaron Beijing Co., Ltd.[*] 康龍化成（北京）新藥技術股份有限公司

(A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 3759)

INSIDE INFORMATION ANNOUNCEMENT REGARDING THE ESTIMATE FOR ANNUAL RESULTS OF 2019

This announcement is made by Pharmaron Beijing Co., Ltd. (the “ Company ” and together with its subsidiaries, the “ Group ”) pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ Listing Rules ”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

I. RESULTS ESTIMATE FOR THE CURRENT PERIOD

1. Period for the results estimate: January 1, 2019 to December 31, 2019

2. Revised results estimate:

   • □Loss □Turn loss into profit □√ Up year-on-year □Down year-on-year □Other

3. Results estimate is as follows:

Item	Current reporting period	Same period last year
Net profit attributableto shareholders ofthe listed Company	Growth compared withthe same period of last year:57% – 67%Profit: 522.8796 millionto 556.1840 million	Profit: 333.0443 million

Note:

• The currency in the above table is in Renminbi (RMB).

1. Discrepancy exists between the figures of the same period of last year in the above table and those in the Annual Report 2018 of the Company disclosed on the Shenzhen Stock Exchange, as the Company started to adopt the new lease and revenue standards on January 1, 2019. The figures of the same period of last year have been adjusted retrospectively in accordance with the requirements of the new lease standard and the Accounting Standards for Business Enterprises No. 28 – Changes in Accounting Policies and Estimates and Corrections of Errors. The information of the same period of last year listed in the table refers to that after such retrospective adjustments, the details of which can be found in the annual report 2019 of the Company to be disclosed on the Shenzhen Stock Exchange.

1

4. Pre-audit status of the revised results estimate

The results estimate of the Company for the reporting period has not been audited by auditors.

5. Reasons for the revision of the results estimate

During the reporting period, the net profit attributable to shareholders of the listed Company of the Company increased compared with the same period of last year, which is mainly due to the orderly implementation of the business plan of the Company. In 2019, the Company reported stable growth in revenue in its principal business, which improved profitability and resulted in corresponding growth in results.

According to the preliminary estimation by the Company, the non-recurrent gains or losses attributable to shareholders of the listed Company for 2019 were approximately RMB40 million to RMB45 million.

6. Other relevant information

• (1) The results estimate is only a preliminary estimation made by the financial department of the Company and has not been audited by auditors.

• (2) Details of the Company’s annual results for 2019 prepared under the China Accounting Standards for Business Enterprises will be disclosed in the annual report 2019 to be published by the Company on the Shenzhen Stock Exchange. Investors are advised to exercise caution and pay attention to the risks involved.

• (3) The financial information set out above is prepared under the China Accounting Standards for Business Enterprises.

By order of the Board Pharmaron Beijing Co., Ltd. 康龍化成（北京）新藥技術股份有限公司 Dr. Lou Boliang* Chairman

Hong Kong, January 21, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Li Lihua, Ms. Chen Guoqin, Ms. Shen Rong and Mr. Tsang Kwan Hung Benson as independent non-executive Directors.

• For identification purposes only

2